Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
PR-7 trial (buserelin): what clinicians have said so far
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
- NCT00003653 ↗
- Completed
- NCIC Clinical Trials Group
- Standard size, estimated: 151–300 verified statements once built
We haven't built an HCP commentary report on PR-7 (buserelin; goserelin; leuprolide in prostate cancer with rising PSA after radiotherapy) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PR-7 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 9 YouTube videos, typically up to 40 once built | |
| 5 posts on X, typically up to 22 once built | |
| 4 podcast episodes, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase III Randomized Trial Comparing Intermittent Versus Continuous Androgen Suppression for Patients With Prostate-Specific-Antigen Progression in the Clinical Absence of Distant Metastases Following Radiotherapy for Prostate Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide; buserelin; cyproterone acetate; flutamide; goserelin; leuprolide acetate; nilutamide
- Arms
- Intermittent Androgen Suppression · Active comparator
- Continuous Androgen Suppression · Active comparator
- Enrollment
- 1,386
- Primary outcomes
- Overall survival
- Sponsor
- NCIC Clinical Trials Group with National Cancer Institute (NCI), SWOG Cancer Research Network
- Start
- Jan 5, 1999
- Primary completion
- Oct 4, 2010
- Results posted
- No
- Registry record
- NCT00003653 · updated Jun 23, 2021
Publications
linked from the registry- Klotz L, Correia A, Zhang W. The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer. Prostate Cancer Prostatic Dis. 2005;8(2):179-83. doi: 10.1038/sj.pcan.4500792. PubMed 15809670
- Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, Frymire E, Malone S, Chin J, Nabid A, Warde P, Corbett T, Angyalfi S, Goldenberg SL, Gospodarowicz MK, Saad F, Logue JP, Hall E, Schellhammer PF, Ding K, Klotz L. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012 Sep 6;367(10):895-903. doi: 10.1056/NEJMoa1201546. PubMed 22931259
- Hamilton RJ, Ding K, Crook JM, O'Callaghan CJ, Higano CS, Dearnaley DP, Horwitz EM, Goldenberg SL, Gospodarowicz MK, Klotz L. The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. Eur Urol. 2021 Apr;79(4):446-452. doi: 10.1016/j.eururo.2020.12.031. Epub 2020 Dec 31. PubMed 33390282
- Klotz L, O'Callaghan C, Ding K, Toren P, Dearnaley D, Higano CS, Horwitz E, Malone S, Goldenberg L, Gospodarowicz M, Crook JM. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol. 2015 Apr 1;33(10):1151-6. doi: 10.1200/JCO.2014.58.2973. Epub 2015 Mar 2. PubMed 25732157